126 Chapter 6 22. Salgado E, Cao Y. Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes. Math Biosci Eng. 2020;18(1):112-131. 23. van der Veen EL, Giesen D, Pot-de Jong L, Jorritsma-Smit A, De Vries EGE, Lub-de Hooge MN. (89)Zrpembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. J Immunother Cancer. 2020;8(2). 24. Jauw YWS, Bensch F, Brouwers AH, et al. Interobserver reproducibility of tumor uptake quantification with (89) Zr-immuno-PET: a multicenter analysis. Eur J Nucl Med Mol Imaging. 2019;46(9):1840-1849. 25. Lesniak WG, Chatterjee S, Gabrielson M, et al. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Bioconjug Chem. 2016;27(9):2103-2110. 26. Niemeijer AN, Oprea Lager DE, Huisman MC, et al. First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer. J Nucl Med. 2021. 27. Dall’Olio FG, Calabro D, Conci N, et al. Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. Eur J Cancer. 2021;150:99-107. 28. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science (New York, NY). 2020;367(6477). 29. Donnem T, Hald SM, Paulsen EE, et al. Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015;21(11):2635-2643. 30. Boscolo A, Fortarezza F, Lunardi F, et al. Combined Immunoscore for Prognostic Stratification of Early Stage NonSmall-Cell Lung Cancer. Front Oncol. 2020;10:564915.
RkJQdWJsaXNoZXIy MTk4NDMw